- Cosentyx 150 mg solution for injection in pre-filled pen
Secukinumab is a fully human IgG1 κ monoclonal antibody that selectively binds to and neutralises the proinflammatory cytokine interleukin‑17A (IL‑17A) Secukinumab works by targeting IL‑17A and inhibiting its interaction with the IL‑17 receptor, which is expressed on various cell types including keratinocytes
- Secukinumab | Drugs | BNF | NICE
View secukinumab information, including dose, uses, side-effects, pregnancy, breast feeding, contra-indications, directions for administration and drug action
- Cosentyx 300mg solution for injection in pre-filled pen | SPC . . .
Secukinumab *Additional information is available within the SPC or upon request to the company Scan the QR code or enter an email to access and share this medicine:
- Cosentyx - European Medicines Agency (EMA)
The active substance in Cosentyx, secukinumab, is a monoclonal antibody, a type of protein, designed to attach to a protein called interleukin?17A Interleukin?17A is involved in inflammation and other immune system processes that cause psoriasis, psoriatic arthritis, axial spondyloarthritis and hidradenitis suppurativa
- Secukinumab - British Association of Dermatologists
What is secukinumab and how does it work? Secukinumab is a drug that has been specially designed to mimic normal human molecules, and for this reason it is classed as a ‘biological’ drug It blocks the activity of a naturally occurring chemical ‘cytokine’ in the body called interleukin-17a (IL-17a)
- secukinumab 150 mg or 300 mg solution for injection in pre-filled pen . . .
secukinumab (Cosentyx®) is accepted for restricted use within NHSScotland Indication under review: for the treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adults with an inadequate response to conventional
- 2 Information about secukinumab | Secukinumab for treating . . . - NICE
Secukinumab (Cosentyx, Novartis) is indicated for the treatment of 'active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic HS therapy'
- Secukinumab | Drugs | BNFC | NICE
View secukinumab information, including dose, uses, side-effects, pregnancy, breast feeding, contra-indications, directions for administration and drug action
|